Cipla Ltd.

BSE: 500087 | NSE: CIPLA
Large Cap | Pharmaceuticals & Drugs
1426.80
-11.95 (-0.83%)
< Home < Back

Cipla gets final approval for Arformoterol Tartrate Inhalation Solution

Date: 23-06-2021

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA). Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.